An interventional study of Perineal-applied electrical stimulation in Urinary Incontinence, sponsored by Elidah, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Elidah, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.
Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 165th largest by enrollment of the 249 interventional ones that give a count, is one of 17 that started in 2024, is one of 144 with no phase, and was the 270th registered.
988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.
Browse Urinary Incontinence studies →33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 18+ · Women only
Duke University · Sites in United States
Ages 18+ · Men only
Ohio State University · Sites in United States
Ages 18+ · Women only
The Methodist Hospital Research Institute · Sites in United States
Ages 22–80 · Men only · Healthy volunteers
University of Miami · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 23 · Phase 3 38 · Phase 4 35
First in 1993; this study’s year is marked. 17 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 66 across 743 interventional studies indexed under Urinary Incontinence.
Median enrollment 75 across the 249 interventional studies, 100 across the 43 observational. Of the 219 that completed or were terminated, 105 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 293 have an industry lead sponsor. The 10 most frequent:
Elidah, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Elidah, Inc. has 2 studies filed under Urinary Incontinence — fewer than ten, so there is no comparison to draw.
16 of the studies in Urinary Incontinence with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT04565925The University of Texas Medical Branch, GalvestonSildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries | 2026-12-01 |
| NCT07534696University of California, Los AngelesEvaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy | 2026-12-31 |
| NCT06226220University of ChicagoPercutaneous Nerve Evaluation Trial Time | 2026-12-31 |
| NCT06369922University of RochesterTENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. | 2027-01-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 293 studies in Urinary Incontinence with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to evaluate the effectiveness of the Elidah neuromuscular stimulation treatment to reduce incontinence in men post-prostatectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Scheduled for robotic assisted laparoscopic prostatectomy.
Device: Perineal-applied electrical stimulation
Small controller that outputs stimulation for stress incontinence and OAB, attached to a male-anatomy thin GelPad placed in the perineal area.
Also known as: Elidah, Elitone, Edytone
24-Hour Urine Leakage Measured by Pad Weight
Urine leakage was assessed using a 24-hour pad weight test. Participants wore absorbent pads for 24 hours, after which the pads were collected and weighed to quantify urine leakage in grams. The reported values represent the mean absolute 24-hour pad weight at Week 6, not the change from baseline. Lower values indicate less urine leakage.
Time frame: 6 weeks
24-Hour Urine Leakage Measured by Pad Weight
Urine leakage was assessed using a 24-hour pad weight test. Participants wore absorbent pads for 24 hours, after which the pads were collected and weighed to quantify urine leakage in grams. The reported values represent the mean absolute 24-hour pad weight at Week 12, not the change from baseline. Lower values indicate less urine leakage.
Time frame: 12 weeks
Number of Participants Without Adverse Events
The number of participants who did not experience an adverse event during the 6-week assessment period. Adverse events were assessed as part of the study's safety evaluation.
Time frame: 6 weeks
Change in Incontinence Quality of Life (I-QOL) Score
Urinary incontinence-related quality of life was assessed using the Incontinence Quality of Life (I-QOL) questionnaire. Each item is scored from 1 to 5. Item scores are summed and transformed to a total score ranging from 0 to 100, with higher scores indicating better quality of life. The reported outcome represents the change in total I-QOL score from baseline to Week 6, calculated as the Week 6 score minus the baseline score. Positive values indicate improved quality of life, while negative values indicate worsening quality of life. The possible change ranges from -100 to +100 points.
Time frame: Baseline to 6 weeks
Percentage Change in Daily Urinary Leakage Episodes
Percentage reduction in the average number of urinary leakage episodes per day, including both stress and urge urinary incontinence episodes, from baseline to Week 6. Percentage reduction was calculated as \[(baseline episodes per day - Week 6 episodes per day) / baseline episodes per day\] × 100. Positive values indicate fewer leakage episodes, while negative values indicate an increase in leakage episodes.
Time frame: Baseline to 6 weeks
Percentage Change in Daily Urinary Leakage Episodes
Percentage reduction in the average number of urinary leakage episodes per day, including both stress and urge urinary incontinence episodes, from baseline to Week 6. Percentage reduction was calculated as \[(baseline episodes per day - Week 6 episodes per day) / baseline episodes per day\] × 100. Positive values indicate fewer leakage episodes, while negative values indicate an increase in leakage episodes.
Time frame: Baseline to 12 weeks
Participants were recruited throughout the U.S. through healthcare provider referrals and social media/online advertising directing candidates to a study website. Ads used terms related to incontinence, bladder leaks, prostate cancer surgery, and prostatectomy. Participant screening began in June 2024 and continued through November 2025. The first participant was enrolled on June 11, 2024.
| Milestone | Arm A |
|---|---|
| Started | 37 |
| Completed | 17 |
| Not completed | 20 |
Urine leakage was assessed using a 24-hour pad weight test. Participants wore absorbent pads for 24 hours, after which the pads were collected and weighed to quantify urine leakage in grams. The reported values represent the mean absolute 24-hour pad weight at Week 6, not the change from baseline. Lower values indicate less urine leakage.
| grams | Arm A |
|---|---|
| 24-Hour Urine Leakage Measured by Pad Weight | 199 ± 305 |
The number of participants who did not experience an adverse event during the 6-week assessment period. Adverse events were assessed as part of the study's safety evaluation.
| Participants | Arm A |
|---|---|
| Number of Participants Without Adverse Events | 17 |
Urinary incontinence-related quality of life was assessed using the Incontinence Quality of Life (I-QOL) questionnaire. Each item is scored from 1 to 5. Item scores are summed and transformed to a total score ranging from 0 to 100, with higher scores indicating better quality of life. The reported outcome represents the change in total I-QOL score from baseline to Week 6, calculated as the Week 6 score minus the baseline score. Positive values indicate improved quality of life, while negative values indicate worsening quality of life. The possible change ranges from -100 to +100 points.
| Scores on a Scale | Arm A |
|---|---|
| Change in Incontinence Quality of Life (I-QOL) Score | 25 ± 21.3 |
Percentage reduction in the average number of urinary leakage episodes per day, including both stress and urge urinary incontinence episodes, from baseline to Week 6. Percentage reduction was calculated as \[(baseline episodes per day - Week 6 episodes per day) / baseline episodes per day\] × 100. Positive values indicate fewer leakage episodes, while negative values indicate an increase in leakage episodes.
| percent reduction | Arm A |
|---|---|
| Percentage Change in Daily Urinary Leakage Episodes | 66.4 ± 25.7 |
Percentage reduction in the average number of urinary leakage episodes per day, including both stress and urge urinary incontinence episodes, from baseline to Week 6. Percentage reduction was calculated as \[(baseline episodes per day - Week 6 episodes per day) / baseline episodes per day\] × 100. Positive values indicate fewer leakage episodes, while negative values indicate an increase in leakage episodes.
| percent reduction | Arm A |
|---|---|
| Percentage Change in Daily Urinary Leakage Episodes | 87 ± 16.8 |
Urine leakage was assessed using a 24-hour pad weight test. Participants wore absorbent pads for 24 hours, after which the pads were collected and weighed to quantify urine leakage in grams. The reported values represent the mean absolute 24-hour pad weight at Week 12, not the change from baseline. Lower values indicate less urine leakage.
| grams | Arm A |
|---|---|
| 24-Hour Urine Leakage Measured by Pad Weight | 32.7 ± 47.3 |
Collected over From Enrollment until the end, up to 12 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A | 0/17 (0%) | 0/17 (0%) | 0/17 (0%) |
Thirty-seven participants enrolled and met eligibility criteria. Seventeen completed the study and were included in the final analysis. The remaining participants did not complete the study because of dropout or incomplete treatment and/or follow-up assessments.
| Age, Categorical(Participants) | Arm A |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 17 |
| >=65 years | 20 |
| Sex: Female, Male(Participants) | Arm A |
|---|---|
| Female | 0 |
| Male | 37 |
| Race and Ethnicity Not Collected(Participants) | Arm A |
|---|
| 24-Hour Pad Weight(grams) | Arm A |
|---|---|
| Mean | 609 ± 572 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2024 to primary completion in Jan 2026, 19 months.
Results were first posted in Nov 2026, 9 months after primary completion.
Of 63 industry-sponsored interventional studies with no phase under Urinary Incontinence, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 19 months is above that.
Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start May 2024 → Jun 2024, primary completion Jun 2026 → Jan 2026 and completion Jun 2026 → Feb 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Elidah, Inc.